Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys

A. Ulu, S. E. Appt, C. Morisseau, S. H. Hwang, P. D. Jones, T. E. Rose, H. Dong, J. Lango, J. Yang, H. J. Tsai, C. Miyabe, C. Fortenbach, M. R. Adams, B. D. Hammock

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE Soluble epoxide hydrolase inhibitors (sEHIs) possess anti-inflammatory, antiatherosclerotic, antihypertensive and analgesic properties. The pharmacokinetics (PK) and pharmacodynamics in terms of inhibitory potency of sEHIs were assessed in non-human primates (NHPs). Development of a sEHI for use in NHPs will facilitate investigations on the role of sEH in numerous chronic inflammatory conditions. EXPERIMENTAL APPROACH PK parameters of 11 sEHIs in cynomolgus monkeys were determined after oral dosing with 0.3 mg·kg -1. Their physical properties and inhibitory potency in hepatic cytosol of cynomolgus monkeys were examined. Dose-dependent effects of the two inhibitors 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin- 4-yl) urea (TPPU) and the related acetyl piperidine derivative, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea (TPAU), on natural blood eicosanoids, were determined. KEY RESULTS Among the inhibitors tested, TPPU and two 4-(cyclohexyloxy) benzoic acid urea sEHIs displayed high plasma concentrations (>10 × IC 50), when dosed orally at 0.3 mg·kg -1. Although the 4-(cyclohexyloxy) benzoic acid ureas were more potent against monkey sEH than piperidyl ureas (TPAU and TPPU), the latter compounds showed higher plasma concentrations and more drug-like properties. The C max increased with dose from 0.3 to 3 mg·kg -1 for TPPU and from 0.1 to 3 mg·kg -1 for TPAU, although it was not linear over this range of doses. As an indication of target engagement, ratios of linoleate epoxides to diols increased with TPPU administration. CONCLUSION AND IMPLICATIONS Our data indicate that TPPU is suitable for investigating sEH biology and the role of epoxide-containing lipids in modulating inflammatory diseases in NHPs.

Original languageEnglish (US)
Pages (from-to)1401-1412
Number of pages12
JournalBritish Journal of Pharmacology
Volume165
Issue number5
DOIs
StatePublished - Mar 2012

Fingerprint

Epoxide Hydrolases
Macaca fascicularis
Pharmacokinetics
Urea
Primates
Benzoic Acid
Epoxy Compounds
Eicosanoids
Linoleic Acid
Cytosol
Antihypertensive Agents
Haplorhini
Analgesics
Anti-Inflammatory Agents
Lipids
Liver
Pharmaceutical Preparations

Keywords

  • atherosclerosis
  • cynomolgus monkeys
  • pharmacokinetics
  • soluble epoxide hydrolase inhibitors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ulu, A., Appt, S. E., Morisseau, C., Hwang, S. H., Jones, P. D., Rose, T. E., ... Hammock, B. D. (2012). Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. British Journal of Pharmacology, 165(5), 1401-1412. https://doi.org/10.1111/j.1476-5381.2011.01641.x

Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. / Ulu, A.; Appt, S. E.; Morisseau, C.; Hwang, S. H.; Jones, P. D.; Rose, T. E.; Dong, H.; Lango, J.; Yang, J.; Tsai, H. J.; Miyabe, C.; Fortenbach, C.; Adams, M. R.; Hammock, B. D.

In: British Journal of Pharmacology, Vol. 165, No. 5, 03.2012, p. 1401-1412.

Research output: Contribution to journalArticle

Ulu, A, Appt, SE, Morisseau, C, Hwang, SH, Jones, PD, Rose, TE, Dong, H, Lango, J, Yang, J, Tsai, HJ, Miyabe, C, Fortenbach, C, Adams, MR & Hammock, BD 2012, 'Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys', British Journal of Pharmacology, vol. 165, no. 5, pp. 1401-1412. https://doi.org/10.1111/j.1476-5381.2011.01641.x
Ulu, A. ; Appt, S. E. ; Morisseau, C. ; Hwang, S. H. ; Jones, P. D. ; Rose, T. E. ; Dong, H. ; Lango, J. ; Yang, J. ; Tsai, H. J. ; Miyabe, C. ; Fortenbach, C. ; Adams, M. R. ; Hammock, B. D. / Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 5. pp. 1401-1412.
@article{3faac8f1d8b94c90a76e8bff2f65aa7c,
title = "Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys",
abstract = "BACKGROUND AND PURPOSE Soluble epoxide hydrolase inhibitors (sEHIs) possess anti-inflammatory, antiatherosclerotic, antihypertensive and analgesic properties. The pharmacokinetics (PK) and pharmacodynamics in terms of inhibitory potency of sEHIs were assessed in non-human primates (NHPs). Development of a sEHI for use in NHPs will facilitate investigations on the role of sEH in numerous chronic inflammatory conditions. EXPERIMENTAL APPROACH PK parameters of 11 sEHIs in cynomolgus monkeys were determined after oral dosing with 0.3 mg·kg -1. Their physical properties and inhibitory potency in hepatic cytosol of cynomolgus monkeys were examined. Dose-dependent effects of the two inhibitors 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin- 4-yl) urea (TPPU) and the related acetyl piperidine derivative, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea (TPAU), on natural blood eicosanoids, were determined. KEY RESULTS Among the inhibitors tested, TPPU and two 4-(cyclohexyloxy) benzoic acid urea sEHIs displayed high plasma concentrations (>10 × IC 50), when dosed orally at 0.3 mg·kg -1. Although the 4-(cyclohexyloxy) benzoic acid ureas were more potent against monkey sEH than piperidyl ureas (TPAU and TPPU), the latter compounds showed higher plasma concentrations and more drug-like properties. The C max increased with dose from 0.3 to 3 mg·kg -1 for TPPU and from 0.1 to 3 mg·kg -1 for TPAU, although it was not linear over this range of doses. As an indication of target engagement, ratios of linoleate epoxides to diols increased with TPPU administration. CONCLUSION AND IMPLICATIONS Our data indicate that TPPU is suitable for investigating sEH biology and the role of epoxide-containing lipids in modulating inflammatory diseases in NHPs.",
keywords = "atherosclerosis, cynomolgus monkeys, pharmacokinetics, soluble epoxide hydrolase inhibitors",
author = "A. Ulu and Appt, {S. E.} and C. Morisseau and Hwang, {S. H.} and Jones, {P. D.} and Rose, {T. E.} and H. Dong and J. Lango and J. Yang and Tsai, {H. J.} and C. Miyabe and C. Fortenbach and Adams, {M. R.} and Hammock, {B. D.}",
year = "2012",
month = "3",
doi = "10.1111/j.1476-5381.2011.01641.x",
language = "English (US)",
volume = "165",
pages = "1401--1412",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys

AU - Ulu, A.

AU - Appt, S. E.

AU - Morisseau, C.

AU - Hwang, S. H.

AU - Jones, P. D.

AU - Rose, T. E.

AU - Dong, H.

AU - Lango, J.

AU - Yang, J.

AU - Tsai, H. J.

AU - Miyabe, C.

AU - Fortenbach, C.

AU - Adams, M. R.

AU - Hammock, B. D.

PY - 2012/3

Y1 - 2012/3

N2 - BACKGROUND AND PURPOSE Soluble epoxide hydrolase inhibitors (sEHIs) possess anti-inflammatory, antiatherosclerotic, antihypertensive and analgesic properties. The pharmacokinetics (PK) and pharmacodynamics in terms of inhibitory potency of sEHIs were assessed in non-human primates (NHPs). Development of a sEHI for use in NHPs will facilitate investigations on the role of sEH in numerous chronic inflammatory conditions. EXPERIMENTAL APPROACH PK parameters of 11 sEHIs in cynomolgus monkeys were determined after oral dosing with 0.3 mg·kg -1. Their physical properties and inhibitory potency in hepatic cytosol of cynomolgus monkeys were examined. Dose-dependent effects of the two inhibitors 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin- 4-yl) urea (TPPU) and the related acetyl piperidine derivative, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea (TPAU), on natural blood eicosanoids, were determined. KEY RESULTS Among the inhibitors tested, TPPU and two 4-(cyclohexyloxy) benzoic acid urea sEHIs displayed high plasma concentrations (>10 × IC 50), when dosed orally at 0.3 mg·kg -1. Although the 4-(cyclohexyloxy) benzoic acid ureas were more potent against monkey sEH than piperidyl ureas (TPAU and TPPU), the latter compounds showed higher plasma concentrations and more drug-like properties. The C max increased with dose from 0.3 to 3 mg·kg -1 for TPPU and from 0.1 to 3 mg·kg -1 for TPAU, although it was not linear over this range of doses. As an indication of target engagement, ratios of linoleate epoxides to diols increased with TPPU administration. CONCLUSION AND IMPLICATIONS Our data indicate that TPPU is suitable for investigating sEH biology and the role of epoxide-containing lipids in modulating inflammatory diseases in NHPs.

AB - BACKGROUND AND PURPOSE Soluble epoxide hydrolase inhibitors (sEHIs) possess anti-inflammatory, antiatherosclerotic, antihypertensive and analgesic properties. The pharmacokinetics (PK) and pharmacodynamics in terms of inhibitory potency of sEHIs were assessed in non-human primates (NHPs). Development of a sEHI for use in NHPs will facilitate investigations on the role of sEH in numerous chronic inflammatory conditions. EXPERIMENTAL APPROACH PK parameters of 11 sEHIs in cynomolgus monkeys were determined after oral dosing with 0.3 mg·kg -1. Their physical properties and inhibitory potency in hepatic cytosol of cynomolgus monkeys were examined. Dose-dependent effects of the two inhibitors 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin- 4-yl) urea (TPPU) and the related acetyl piperidine derivative, 1-trifluoromethoxyphenyl-3-(1-acetylpiperidin-4-yl) urea (TPAU), on natural blood eicosanoids, were determined. KEY RESULTS Among the inhibitors tested, TPPU and two 4-(cyclohexyloxy) benzoic acid urea sEHIs displayed high plasma concentrations (>10 × IC 50), when dosed orally at 0.3 mg·kg -1. Although the 4-(cyclohexyloxy) benzoic acid ureas were more potent against monkey sEH than piperidyl ureas (TPAU and TPPU), the latter compounds showed higher plasma concentrations and more drug-like properties. The C max increased with dose from 0.3 to 3 mg·kg -1 for TPPU and from 0.1 to 3 mg·kg -1 for TPAU, although it was not linear over this range of doses. As an indication of target engagement, ratios of linoleate epoxides to diols increased with TPPU administration. CONCLUSION AND IMPLICATIONS Our data indicate that TPPU is suitable for investigating sEH biology and the role of epoxide-containing lipids in modulating inflammatory diseases in NHPs.

KW - atherosclerosis

KW - cynomolgus monkeys

KW - pharmacokinetics

KW - soluble epoxide hydrolase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84863115555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863115555&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01641.x

DO - 10.1111/j.1476-5381.2011.01641.x

M3 - Article

C2 - 21880036

AN - SCOPUS:84863115555

VL - 165

SP - 1401

EP - 1412

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 5

ER -